Latest ICER Report Looks at the Value of Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is the latest high-profile disease for which the Institute for Clinical and Economic Review (ICER) has constructed a “value framework” for assessing and comparing available drug treatments. In April, ICER issued a comprehensive, 529-page report on targeted immune modulators (TIMs) for RA that covers 14 medicines—all but two biologics, and none biosimilars. […]

Read More